Page last updated: 2024-12-09

1-(4-chloro-2,5-dimethoxyphenyl)sulfonylbenzotriazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(4-chloro-2,5-dimethoxyphenyl)sulfonylbenzotriazole, also known as **CDMT**, is a **sulfonylbenzotriazole derivative** that has garnered significant interest in research due to its unique properties and potential applications. Here's a breakdown of its importance:

**What it is:**

* **Structure:** It consists of a benzotriazole core with a sulfonyl group attached at position 1 and a 4-chloro-2,5-dimethoxyphenyl substituent on the sulfonyl group. This specific combination of features is crucial for its function.
* **Chemical Properties:** It is a white to off-white solid that is soluble in organic solvents but not in water.

**Why it's important in research:**

1. **Antioxidant and Anti-inflammatory Activities:** CDMT has shown promising activity against various reactive oxygen species (ROS) and free radicals, acting as a potent antioxidant. This makes it relevant for research investigating:
* **Oxidative Stress and Disease:** Understanding and mitigating oxidative stress is crucial for studying neurodegenerative diseases, cardiovascular disease, and aging.
* **Inflammation:** CDMT's ability to inhibit inflammatory processes is valuable for studying autoimmune diseases, inflammatory bowel disease, and other inflammatory conditions.

2. **Photochemistry and Photostabilization:**
* **Light Sensitivity:** CDMT has a strong absorbance in the UV region, making it sensitive to light.
* **Stabilizer:** Its ability to absorb UV light and dissipate energy makes it a potential candidate as a photostabilizer for materials and products susceptible to degradation under UV exposure.

3. **Organic Synthesis and Material Science:**
* **Versatile Building Block:** CDMT can serve as a starting material in organic synthesis to create new and complex molecules with diverse properties.
* **Material Properties:** Its unique structure and properties make it potentially valuable in the development of new materials with specific functionalities.

4. **Biological Studies:**
* **Drug Discovery:** CDMT's chemical structure and biological activity make it a potential lead compound for developing novel therapeutic agents.
* **Target Identification:** Researchers can use CDMT as a tool to investigate specific biological targets involved in disease processes.

**Current Research:**

Currently, research on CDMT focuses on:

* Exploring its therapeutic potential for various diseases.
* Understanding its mechanism of action in different biological systems.
* Developing new derivatives and analogs with enhanced properties.

**Overall, 1-(4-chloro-2,5-dimethoxyphenyl)sulfonylbenzotriazole (CDMT) is a fascinating molecule with a broad range of potential applications in research. Its antioxidant, photochemical, and synthetic properties make it a valuable tool for studying a wide array of biological and material science phenomena.**

Cross-References

ID SourceID
PubMed CID1289024
CHEMBL ID1393097
CHEBI ID94045

Synonyms (19)

Synonym
smr000075623
MLS000097007
1-[(4-chloro-2,5-dimethoxyphenyl)sulfonyl]-1h-1,2,3-benzotriazole
CBKINASE1_017552
CBKINASE1_005152
BRD-K48823327-001-01-8
1-(4-chloro-2,5-dimethoxyphenyl)sulfonylbenzotriazole
MLS002546214
AKOS001288203
STK919124
1-[(4-chloro-2,5-dimethoxyphenyl)sulfonyl]-1h-benzotriazole
HMS2318E04
CHEMBL1393097
AP-263/42234245
CHEBI:94045
SR-01000272466-1
sr-01000272466
Z57705172
Q27165797
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency8.91250.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID886
ATAD5 protein, partialHomo sapiens (human)Potency4.61090.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978
thyroid stimulating hormone receptorHomo sapiens (human)Potency2.51190.001318.074339.8107AID926; AID938
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency4.46680.28189.721235.4813AID2326
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency56.23410.036619.637650.1187AID1466; AID2242
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
survival motor neuron protein isoform dHomo sapiens (human)Potency12.58930.125912.234435.4813AID1458
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency56.23413.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency56.23413.548118.039535.4813AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]